

# Characterization of Plasmid Co-Harboring NDM-1 and SHV-12 from a Multidrug-Resistant *Citrobacter freundii* Strain ZT01-0079 in China

This article was published in the following Dove Press journal:  
*Infection and Drug Resistance*

Tingyan Zhang<sup>1,2,\*</sup>  
Yanfeng Lin<sup>2,3,\*</sup>  
Peihan Li<sup>2,3,\*</sup>  
Zhonghong Li<sup>2</sup>  
Xiong Liu<sup>2</sup>  
Jinhui Li<sup>2</sup>  
Lizhong Li<sup>2</sup>  
Kaiying Wang<sup>2,3</sup>  
Zhongdong Liu<sup>1</sup>  
Peng Li<sup>2</sup>  
Lanfen Lu<sup>4</sup>  
Hongyan Wang<sup>1</sup>

<sup>1</sup>School of Chemistry and Chemical Engineering, Henan University of Technology, Zhengzhou, People's Republic of China; <sup>2</sup>Chinese PLA Center for Disease Control and Prevention, Beijing, People's Republic of China; <sup>3</sup>Academy of Military Medical Sciences, Beijing, People's Republic of China; <sup>4</sup>Department of Laboratory Diagnosis, Sun Yat-Sen University Affiliated Zhongshan Hospital, Zhongshan, Guangdong, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Peng Li; Hongyan Wang  
Email jiekenlee@126.com;  
18623717897@163.com

**Background:** The emergence of multidrug-resistant *Citrobacter freundii* poses daunting challenges to the treatment of clinical infections. The purpose of this study was to characterize the genome of a *C. freundii* strain with an IncX3 plasmid encoding both the *bla*<sub>NDM-1</sub> and *bla*<sub>SHV-12</sub> genes.

**Methods:** Strain ZT01-0079 was isolated from a clinical urine sample. The Vitek2 system was used for identification and antimicrobial susceptibility testing. The presence of *bla*<sub>NDM-1</sub> was detected by PCR and sequencing. Conjugation experiments and Southern blotting were performed to determine the transferability of the *bla*<sub>NDM-1</sub>-carrying plasmid. Nanopore and Illumina sequencing were performed to better understand the genomic characteristics of the strain.

**Results:** Strain ZT01-0079 was identified as *C. freundii*, and the coexistence of *bla*<sub>NDM-1</sub> and multiple drug resistance genes was confirmed. Electrophoresis and Southern blotting showed that *bla*<sub>NDM-1</sub> was located on a ~53kb IncX3 plasmid. The NDM-1-encoding plasmid was successfully transferred at a frequency of  $1.68 \times 10^{-3}$ . Both the *bla*<sub>NDM-1</sub> and *bla*<sub>SHV-12</sub> genes were located on the self-transferable IncX3 plasmid.

**Conclusion:** The rapid spread of the IncX3 plasmid highlights the importance of continuous monitoring of the prevalence of NDM-1-encoding *Enterobacteriaceae*. Mutations of existing carbapenem resistance genes will bring formidable challenges to clinical treatment.

**Keywords:** *C. freundii*, whole-genome sequencing, genomics analysis

## Background

New Delhi metallo-β-lactamase-1 (NDM-1) is an enzyme capable of hydrolyzing most β-lactam antibiotics. Since its first detection in 2009 in *Klebsiella pneumoniae*,<sup>1</sup> 21 NDM variants have been reported from various *Enterobacteriaceae* species.<sup>2–10</sup> The increasing prevalence of NDM-producing bacteria is due primarily to intra- and inter-species exchanges of a variety of self-transferring plasmids. The coexistence of NDM and other resistance genes on a single plasmid is being reported with increasing frequency and confers high-level carbapenem resistance, which poses daunting challenges to clinical management.<sup>7,11</sup>

*Citrobacter freundii*, a member of the *Enterobacteriaceae* family, is a constituent of the commensal intestinal microbiota of animal and humans.<sup>12</sup> However, it can cause diarrhea, sepsis,<sup>13</sup> meningitis,<sup>14</sup> respiratory<sup>15</sup> and urinary tract,<sup>16</sup> and can serve as a reservoir of antibiotic resistance genes. In recent years, due to the abuse of antibiotics, *C. freundii* has acquired increasing resistance to

common antibiotics.<sup>17</sup> In addition, *bla*<sub>NDM-1</sub>-positive *C. freundii* has been reported in numerous countries that including but are not limited to China,<sup>2-5</sup> India,<sup>6,7</sup> Japan,<sup>8</sup> Denmark<sup>9</sup> and South Africa.<sup>10</sup> We report a carbapenem-resistant strain of *C. freundii* with coexistent *bla*<sub>NDM-1</sub> and *bla*<sub>SHV-12</sub> genes on a transferrable IncX3 plasmid. Antimicrobial susceptibility tests, conjugation experiments, and whole-genome sequencing were performed to study the molecular characteristics of the multidrug-resistant strain.

## Methods

### Bacterial Identification and Isolation

Strain ZT01-0079 was isolated from a urine sample of a patient with dysuria in 2018, in Guangzhou, China. Species identification was conducted by using the VITEK2 compact system (BioMérieux, France) and confirmed by 16S rDNA sequencing. The *bla*<sub>NDM</sub> gene was detected by PCR amplification as previously described.<sup>18</sup> The isolate was obtained by conventional collection, and verbal consent was obtained as no personal information is included. All experiments were conducted in accordance with relevant regulations and approved by the Chinese PLA Center for Disease Control and Prevention.

### Susceptibility Testing

The VITEK2 system (BioMérieux, France) with AST-GN09 card (bioMérieux) was used for minimum inhibitory concentrations (MICs) determinations of strain ZT01-0079 and transconjugants. The E-test method was used to determine the MIC value of meropenem. Results were interpreted in accordance with the Clinical and Laboratory Standards Institute (CLSI)<sup>19</sup> guidelines. The following agents were tested: amikacin, aztreonam, nitrofurantoin, ciprofloxacin, piperacillin, gentamicin, cefepime, ceftriaxone, ceftazidime, tobramycin, imipenem, levofloxacin and sulfamethoxazole/trimethoprim.

### S1-PFGE, Southern Blotting and Conjugation Experiment

The genomic DNA of strain ZT01-0079 was prepared in an agarose plug with S1 endonuclease (Takara, Dalian, China). PFGE separates DNA fragments by the CHEF-DR III system (Bio-Rad, Hercules, USA). PFGE runs for 15 h under the conditions of a gradient of 6.0 V/cm, a pulse time of 0.20–26.0 s and an angle of 120°. The plasmid DNA was transferred to a positively charged

nylon membrane (Solabio, China) and hybridized with a digoxigenin-labeled *bla*<sub>NDM-1</sub> specific probe.

Strain ZT01-0079 and *Escherichia coli* strain J53 were used as donors and recipients, respectively. The ZT01-0079 and J53 strains were mixed in (LB) broth at a ratio of 1:3 and incubated at 37°C for 18 h. Transconjugants were selected on MacConkey agar plates containing meropenem (4 µg/mL) and sodium azide (150 µg/mL) for 12 h. A susceptibility test was performed to determine the horizontal transferability of drug resistance, and the corresponding transconjugants were confirmed by PCR and sequencing of the NDM gene and 16S rRNA gene, S1-PFGE and southern blotting. The frequency of conjugation was calculated as the ratio of transconjugants to recipient cells.

### Whole Genome Sequencing and Comparative Genome Analysis

Genomic DNA was extracted from strain ZT01-0079 using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Whole-genome sequencing was performed using the Illumina HiSeq 2500 sequencer in Novogene (Beijing, China), with a coverage of 109X. The nanopore sequencing library was prepared using the rapid sequencing kit SQK-RAD004 (Oxford Nanotechnology, UK). The mixed assembly of Illumina and Nanopore (Oxford Nanotechnology, UK) reads was performed using Unicycler<sup>20</sup> (v0.4.7). PlasmidFinder<sup>21</sup> (<https://cge.cbs.dtu.dk/services/PlasmidFinder/>) was used to determine the plasmid replicon type. Genotyping was performed to query the seven domesticated genes (*aspC*, *clpX*, *fadD*, *mdh*, *arcA*, *dnaG* and *lysP*) via the multi-locus sequence typing MLST web service<sup>22</sup> (<https://cge.cbs.dtu.dk/services/MLST/>).

### Nucleotide Sequence Accession Numbers

The complete sequence of the ZT01-0079 strain and plasmids pZY-1, pZY-2 and pZY-NDM1 have been deposited in GenBank with accession numbers CP055247, CP055248, CP055249 and CP022050.

## Results


### Microbiological Features of Strain ZT01-0079

Strain ZT01-0079 was identified as *C. freundii*. Susceptibility testing showed that *C. freundii* ZT01-0079 exhibited resistance to aztreonam, nitrofurantoin, ciprofloxacin, piperacillin, cefepime, ceftriaxone, ceftazidime,

tobramycin, levofloxacin, and imipenem (Table 1). S1-PFGE revealed that *C. freundii* ZT01-0079 contained three plasmids (~143kb, ~89kb and ~53kb) (Figure 1). Conjugation and southern blotting showed that the *bla*<sub>NDM-1</sub> gene was located on the ~53kb plasmid and only the NDM-1-carrying plasmid was successfully transferred to J53 at a frequency of  $1.69 \times 10^{-3}$  events per donor cell. Transconjugants acquired resistance to aztreonam, piperacillin, cefepime, ceftriaxone, ceftazidime, and imipenem (Table 1). The E-test showed that strain ZT01-0079 (MIC = 8) and transconjugants (MIC = 8) are both resistant to meropenem. In silico, MLST found that *C. freundii* ZT01-0079 belongs to sequence type 19 (ST19). In addition to *bla*<sub>NDM-1</sub>, *C. freundii* ZT01-0079 carried multiple resistance genes including *bla*<sub>SHV-12</sub>, *bla*<sub>CTX-M-55</sub>, *bla*<sub>CMY-152</sub>, *aph* (3'')-Ib, *aph* (6)-Id, *bla*<sub>TEM-1B</sub>, *sul2*, *floR*, *tet*(A) and *aac*(3)-IId. Both the 89kb plasmid (named pZY-1) and the 143kb plasmid (named pZY-2) carried resistance genes including *aph*(3'')-Ib, *aph*(6)-Id (aminoglycoside resistance) and *sul2* (sulfonamide resistance). pZY-1 also carried the *bla*<sub>CTX-M-55</sub> (fluoroquinolone resistance), *bla*<sub>TEM-1B</sub> (cephalosporin resistance), *floR* (florfenicol resistance), *tet*(A) (tigecycline resistance) genes. pZY-2 also carried the *aac*(3)-IId (aminoglycoside resistance) gene, while the 53kb plasmid (named pZY-NDM1) carried the *bla*<sub>NDM-1</sub> and *bla*<sub>SHV-12</sub> genes (carbapenem resistance).

**Table 1** Antibiotic Susceptibilities of *C. freundii* ZT01-0079, Transconjugant and *E. coli* J53 (Recipient)

Antimicrobial	MIC (μg/mL)		
	ZT01-0079	Transconjugant	Recipients ( <i>E. coli</i> J53)
Amikacin	8	≤2	≤2
Aztreonam	≥64	16	≤1
Nitrofurantoin	128	≤16	≤16
Ciprofloxacin	≥4	≤0.25	≤0.25
Piperacillin	≥128	64	≤4
Gentamicin	≥16	≤1	≤1
Cefepime	≥64	8	≤4
Ceftriaxone	≥64	≥64	≤4
Ceftazidime	≥64	≥64	≤1
Tobramycin	≥16	≤1	≤1
Imipenem	≥16	≥16	≤1
Levofloxacin	≥8	≤0.25	≤0.25
Sulfamethoxazole-trimethoprim	≤20	≤20	≤20



**Figure 1** S1-PFGE pattern for strain ZT01-0079 and Southern blot analysis of *bla*<sub>NDM-1</sub> genes. Lane marker, *Salmonella* serotype Braenderup strain H9812 as a reference size standard; Lane 1, PFGE result of S1-digested plasmid DNA of strain ZT01-0079; Lane 2, PFGE patterns for S1-digested plasmid DNA of the transconjugants J53; Lane 3, Southern blotting of strain ZT01-0079 with the probes specific to the *bla*<sub>NDM-1</sub> gene. The black arrows indicate the plasmid pZY-NDM1.

## Genetic Analysis of pZY-NDM1

Plasmid pZY-NDM1 is a 53573 bp circular plasmid with an average GC content of 49.24% and has 76 open reading frames. pZY-NDM1 belongs to type IncX3. BLAST comparison disclosed that the genome sequence of pZY-NDM1 shared >99% similarity with plasmids pNDM-HK3694 (Genbank accession JX104760.1) and p309074-NDM (Genbank accession MH909346.1). These three plasmids share a typical IncX plasmid backbone composed of replication (*repB*), plasmid stability (*parA*, *parB*), plasmid maintenance (*hns*, *top*) and type IV secretion system (*taxA*, *taxB*, *taxC*, *VirD1*, *VirD2*, *VirD3-4*, *VirD5* and *VirD6*, *VirD8*, *VirD9*, *VirD10*, *VirD11*) encoding regions (Figure 2A). The 19.66 kb



transposon are divided into two incomplete  $\Delta umuD1$  and  $\Delta umuD2$ , which may serve as insertion sites of regions containing the  $bla_{SHV-12}$ -carrying transposons, Tn125 variant and  $tnpA$  (Figure 2B).

## Discussion

The prevalence of NDM-1-producing bacteria is receiving increasing attention as a threat to global health. Most  $bla_{NDM-1}$ -positive isolates of diverse species of *Enterobacteriaceae* show high-level resistance to  $\beta$ -lactam antibiotics. Concurrently, the  $bla_{NDM-1}$  gene has also spread in many environmental and animal reservoirs, such as sewage, rivers, soil, and many mammals and poultry in Asia and the Middle East.<sup>2,9,12,24</sup> However, reports on *C. freundii* are still rare. Therefore, we investigated the genomic characteristics of multidrug-resistant *C. freundii* (strain ZT01-0079) isolated from a clinical urine specimen. This strain has the IncX3 plasmid pZY-NDM1 that co-harbors  $bla_{NDM-1}$  and  $bla_{SHV-12}$ . Plasmids belonging to the IncX3 group usually have a wide host range and self-conjugation.<sup>12,25,26</sup> Host-range plasmids usually appear with variable frequencies ranging from  $10^{-3}$  to  $10^{-6}$ .<sup>27</sup> pZY-NDM1 showed a relatively high transfer frequency, proving its great potential for cross-species transfer.

The coexistence of  $bla_{NDM-1}$  and other  $\beta$ -lactamase genes in IncX3 plasmids, which have a broad host range, mediates resistance to broad-spectrum antibiotics, such as carbapenems and cephalosporins, and can be transferred between *Enterobacteriaceae*.<sup>28</sup> Notably, there are few reports of such plasmids in *C. freundii*, and there is a potential risk of spreading this plasmid and monitoring should be strengthened.

## Conclusions

In summary, we characterized the genomic basis of multidrug resistance in *C. freundii* ZT01-0079 strain. MLST revealed that strain ZT01-0079 belongs to ST19. ZT01-0079 carried multiple  $bla$  genes, which increased the level of carbapenem resistance. The transferable plasmid pZY-NDM1 carries  $bla_{NDM-1}$  and  $bla_{SHV-12}$  genes, and may thereby serve as a common vector for the rapid dissemination of carbapenemase-encoding genes. Our findings further underscore the threat of increased NDM-1 prevalence in *Enterobacteriaceae* and emphasize that increased resources and effort should be dedicated to monitoring the potentially rapid spread of NDM-1-encoding plasmids.

## Data Sharing Statement

Genomic and plasmid sequences of strain ZT01-0079 were deposited in GenBank under accession CP055247, CP055248, CP055249 and CP022050.

## Ethics Approval and Informed Consent

The authors state that all experimental protocols were approved by the institutional ethics committees of Academy of Military Medical Sciences.

## Consent for Publication

The clinically separated samples used in this study are routine hospital procedures. We do not use patients' personal information, so written consent is not required.

## Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

## Funding

The study was supported by grants from the National Major Science and Technology Project (no. 2018ZX10305410), the National Key Research and Development Project (no. 2018YFC1200100) and the National Nature Science Foundation of China (no. 31900151).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene,  $bla_{NDM-1}$ , and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother*. 2009;53(12):5046–5054. doi:10.1128/AAC.00774-09
2. Wu W, Espedido B, Feng Y, Zong Z. *Citrobacter freundii* carrying  $bla_{KPC-2}$  and  $bla_{NDM-1}$ : characterization by whole genome sequencing. *Sci Rep*. 2016;6:30670. doi:10.1038/srep30670
3. Feng J, Qiu Y, Yin Z, et al. Coexistence of a novel KPC-2-encoding MDR plasmid and an NDM-1-encoding pNDM-HN380-like plasmid in a clinical isolate of *Citrobacter freundii*. *J Antimicrob Chemother*. 2015;70(11):2987–2991. doi:10.1093/jac/dkv232
4. Du XX, Wang JF, Fu Y, et al. Genetic characteristics of  $bla_{NDM-1}$ -positive plasmid in *Citrobacter freundii* isolate separated from a clinical infectious patient. *J Med Microbiol*. 2013;62:1332–1337. doi:10.1099/jmm.0.057091-0

5. Huang YM, Zhong LL, Zhang XF, et al. NDM-1-producing *Citrobacter freundii*, *Escherichia coli*, and *Acinetobacter baumannii* identified from a single patient in China. *Antimicrob Agents Chemother*. 2015;59:5073–5077. doi:10.1128/AAC.04682-14
6. Dolejska M, Villa L, Poirel L, Nordmann P, Carattoli A. Complete sequencing of an IncHI1 plasmid encoding the carbapenemase NDM-1, the ArmA 16S RNA methylase and a resistance-nodulation-cell division/multidrug efflux pump. *J Antimicrob Chemother*. 2013;68:34–39. doi:10.1093/jac/dks357
7. Poirel L, Ros A, Carricajo A, et al. Extremely drug-resistant *Citrobacter freundii* isolate producing NDM-1 and other carbapenemases identified in a patient returning from India. *Antimicrob Agents Chemother*. 2011;55:447–448. doi:10.1128/AAC.01305-10
8. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. *Mdecine et Maladies Infectieuses*. 2013;44(2):51–56. doi:10.1016/j.medmal.2013.11.007
9. Hammerum AM, Hansen F, Nielsen HL, et al. Use of WGS data for investigation of a long-term NDM-1-producing *Citrobacter freundii* outbreak and secondary in vivo spread of bla<sub>NDM-1</sub> to *Escherichia coli*, *Klebsiella pneumoniae* and *Klebsiella oxytoca*. *J Antimicrobial Chemother*. 2016;71:3117–3124. doi:10.1093/jac/dkw289
10. Rubin JE, Peirano G, Peer AK, et al. NDM-1-producing *Enterobacteriaceae* from South Africa: moving towards endemicity? *Diagn Microbiol Infect Dis*. 2014;79(3):378–380. doi:10.1016/j.diagmicrobio.2014.04.003
11. Wu W, Feng Y, Carattoli A, Zong Z. The emergence of *Enterobacter cloacae* producing both KPC and NDM carbapenemases: characterization by whole genome sequencing. *Antimicrob Agents Chemother*. 2015;59:6625–6628. doi:10.2217/fmb-2017-0067
12. Yang L, Li P, Liang B, et al. Multidrug-resistant *Citrobacter freundii* ST139 co-producing NDM-1 and CMY-152 from China. *Sci Rep*. 2018;8(1):10653. doi:10.1038/s41598-018-28879-9
13. Pfaller MA, Jones RN, Marshall SA, et al. Inducible amp C  $\beta$ -lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). *Diagn Microbiol Infect Dis*. 1997;28:211–219. doi:10.1016/S0732-8893(97)00064-3
14. Joaquin A, Khan S, Russell N, et al. Neonatal meningitis and bilateral cerebellar abscesses due to *Citrobacter freundii*. *Pediatr Neurosurg*. 2008;17(1):23–24. doi:10.1159/000120561
15. Fujii T, Inoue Y, Sakata S, et al. Coexisting respiratory tract infection and bacteremia or sepsis caused by the same bacterium. *Kansenshogaku Zasshi*. 1994;68(2):217–225. doi:10.11150/kansenshogakuzasshi1970.68.217
16. Mathew JL. Antibiotic prophylaxis following urinary tract infection in children: a systematic review of randomized controlled trials. *Indian Pediatr*. 2010;47(7):599–605. doi:10.1007/s13312-010-0127-x
17. Bodey GP. Managing Infections in the Immunocompromised Patient. *Clin Infect Dis*. 2005;40(Supplement4):S239–S239. doi:10.1086/427328.
18. Zhang X, Lou D, Xu Y, et al. First identification of coexistence of bla<sub>NDM-1</sub> and bla<sub>CMY-42</sub> among *Escherichia coli* ST167 clinical isolates. *BMC Microbiol*. 2013;13:282. doi:10.1186/1471-2180-13-282
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-eighth informational supplement. M100-S28. Wayne, PA, USA: CLSI; 2018.
20. Wick RR, Judd LM, Gorrie CL, Holt KE, Phillippy AM. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput Biol*. 2017;13(6):e1005595. doi:10.1371/journal.pcbi.1005595
21. Carattoli A, Zankari E, García-Fernández A, Larsen MV, Lund O, Villa L. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother*. 2014;58(7):3895–3903. doi:10.1128/AAC.02412-14
22. Larsen MV, Cosentino S, Rasmussen S, et al. Multilocus sequence typing of total-genome-sequenced bacteria. *J Clin Microbiol*. 2012;50(4):1355–1361. doi:10.1128/JCM.06094-11
23. Abe R, Akeda Y, Sakamoto N, et al. Genomic characterisation of a novel plasmid carrying bla<sub>IMP-6</sub> of carbapenem-resistant *Klebsiella pneumoniae* isolated in Osaka, Japan. *J Glob Antimicrob Resist*. 2019;21:195–199. doi:10.1016/j.jgar.2019.10.003
24. Zong Z, Zhang X. bla<sub>NDM-1</sub>-carrying *Acinetobacter johnsonii* detected in hospital sewage. *J Antimicrob Chemother*. 2013;68:1007–1010. doi:10.1093/jac/dks505
25. Ho PL, Li Z, Lo WU, et al. Identification and characterization of a novel incompatibility group X3 plasmid carrying bla<sub>NDM-1</sub> in *Enterobacteriaceae* isolates with epidemiological links to multiple geographical areas in China. *Emerg Microbes Infect*. 2012;1(11):e39. doi:10.1038/emi.2012.37
26. Suzuki H, Yano H, Brown CJ, et al. Predicting plasmid promiscuity based on genomic signature. *J Bacteriol*. 2010;192(22):6045–6055. doi:10.1128/JB.00277-10
27. Grohmann E, Muth G, Espinosa M. Conjugative plasmid transfer in gram-positive bacteria. *Microbiol Mol Biol Rev*. 2003;67(2):277–301. doi:10.1128/mmbr.67.2.277-301
28. Tardif G, Grant RB. Transfer of plasmids from *Escherichia coli* to *Pseudomonas aeruginosa*: characterization of a *Pseudomonas aeruginosa* mutant with enhanced recipient ability for enterobacterial plasmids. *Antimicrob Agents Chemother*. 1983;24(2):201–208. doi:10.1128/AAC.24.2.201

## Infection and Drug Resistance

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress